Thalidomide Pharmion(R) Receives Marketing Approval From Australian Therapeutic Goods Administration For Treatment Of Newly Diagnosed Multiple Myeloma
Celgene International SÃ rl (NASDAQ: CELG) announced the Australian Therapeutic Goods Administration (TGA) approved a supplemental filing granting Thalidomide Pharmion marketing approval for use in combination with melphalan and prednisone for patients with untreated multiple myeloma or ineligible for high dose chemotherapy.
More: continued here
Filed under: Cancer on April 11th, 2008